Inventaire - your friends and communities are your best library - Inventaire

The Economics of Reproducibility in Preclinical Research

published in: PLOS Biology

date of publication: 2015-06

language: English

main subject: reproducibility, replication crisis

Cites articles 26

Date

Title

Authors

2015-01-01

Reproducibility in science: improving the standard for basic and preclinical research

John Ioannidis
2015-01-01

Science isn't science if it isn't reproducible

Kevin A. Roth, Audra E Cox
2014-10

Reproducibility of results in preclinical studies: a perspective from the bone field
2014-05

Distinguishing between exploratory and confirmatory preclinical research will improve translation

Ulrich Dirnagl, Jonathan Kimmelman
2014-01

Biomedical research: increasing value, reducing waste

John Ioannidis, Ulrich Dirnagl, Rustam Al-Shahi Salman, Malcolm Macleod, Susan Michie, Paul P. Glasziou, Iain Chalmers
2014-01-30

Policy: NIH plans to enhance reproducibility

Francis Collins
2014-12-01

Cell Biology. Fixing problems with cell lines

Francis Collins, Jennifer Lippincott-Schwartz, Jon R. Lorsch
2014-08-14

Financial costs and personal consequences of research misconduct resulting in retracted publications

Ferric Fang, Arturo Casadevall
2014-07-17

The increasing urgency for standards in basic biologic research
2014-01-08

Increasing value and reducing waste in research design, conduct, and analysis

David Moher, John Ioannidis, Robert Tibshirani, Malcolm Macleod, Mark A. Hlatky, Muin J. Khoury
2014-01-07

Two years later: journals are not yet enforcing the ARRIVE guidelines on reporting standards for pre-clinical animal studies

Sandra Amor
2014-01-01

Asia's ascent--global trends in biomedical R&D expenditures

Jeffrey D Steinberg, Reshma Jagsi
2014-12-02

The impact of preclinical irreproducibility on drug development

Lynn P. Freedman
2014-01-01

Reproducibility: Fraud is not the big problem.
2013-09-05

On the reproducibility of science: unique identification of research resources in the biomedical literature

Nicole Vasilevsky, Melissa Haendel
2013-12-01

Rethinking reanalysis

Frederick J Zimmerman, Dimitri A. Christakis
2012-10-11

A call for transparent reporting to optimize the predictive value of preclinical research

Story C. Landis, John R. Huguenard, Robert B. Darnell, David Howells, Susan Amara, Oswald Steward, Malcolm Macleod, Robert J Ferrante, Stanley E Lazic, Shai D Silberberg, Howard E. Gendelman
2012-03-28

Drug development: Raise standards for preclinical cancer research
2012

Tracking replicability as a method of post-publication open evaluation

Adena Schachner
2011-08-31

Believe it or not: how much can we rely on published data on potential drug targets?
2011-11-10

Replication and reproducibility in spinal cord injury research.

Oswald Steward, Naomi Kleitman
2011-08

Climbing atop the Shoulders of Giants: The Impact of Institutions on Cumulative Research
2010-03

Publication bias in reports of animal stroke studies leads to major overstatement of efficacy

H Bart van der Worp, Emily Sena, David Howells, Malcolm Macleod, Philip M W Bath
2008-06-01

What is missing from descriptions of treatment in trials and reviews?

Carl Heneghan, Paul P. Glasziou
2007-11

The costs of using unauthenticated, over-passaged cell lines: how much more data do we need?

Yvonne A. Reid
2004-07-01

Cell line cross-contamination: how aware are Mammalian cell culturists of the problem and how to monitor it?

Article - wd:Q28548038

Welcome to Inventaire

the library of your friends and communities

you are offline